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Growth hormone (GH) variants have been studied for the structure-function relationship of the 
molecule. The presence of a potential alternate splicing point in mRNA in bGH gene at exon 3, similar to 
hGH has been reported by workers. Early investigation on the characteristics of the chemistry of 20k 
oGH showed that the molecule was produced by site-directed mutagenesis by deleting amino acid 
residues 33-46 and the resultant DNA was expressed in E. coli under the control of lac promoter in pUC 
based plasmid. The mutant protein remained insoluble and did not refold. To investigate the effect of 
deletion on the chemistry of the molecule, computational biology tools were employed. The mutant with 
the deletion of amino acid residues 33-46, was designed and the model was visualized on computer. 
The structure of 20k bGH was compared with bGH and dissected for hydrogen bonds and hydro-
phobicity. Computational biology tools were helpful in elucidating the role of 33-46 amino acid residues 
domain in the chemistry of the molecule. Furthermore, it was revealed that removal of amino acid 
residues 33-46 which formed the hydrogen bonds involving Glu 33, Gln 46, Pro 38, Arg 42, Tyr 43,Ala 
51, Thr 48, Asn 47, led to the formation of new hydrogen bonds between Thr 33, Tyr 144, Asn 32, Asn 32 
and Ser and Asp 153. The removal of the amino acids 33-46 decreased the hydro-phobicity of the first 
helix of bGH molecule, as compared to 20k hGH, thus altering the solubility of the molecule, confirming 
the earlier reported results for ovine growth hormone with same deletion. 
 





Growth hormone (GH) is a polypeptide chain which is 
involved in a number of anabolic processes (Wallis, 
1985). A number of reports are available on the primary 
structure, gene cloning and expression of growth 
hormone gene (Santome, 1971; Sami, 2006; Sereikeite, 
2007; Wallis, 1973, 1985, 2001, 2005, 2006; Verma, 
1999; Yato, 1988; Vize, 1987). GH gene in ruminants 
comprised of 2.1 KB present at chromosome 19. Bovine 
GH gene (bGH) has 5 exons and 4 introns. Removal of 
introns is a critical step in the transcription of the protein, 
as any event at a potential splicing point could introduce 
some changes in the nucleotide sequence which could 
lead to the expression of a GH variant, as it happened in 
the case of 20k hGH (Denoto, 1981; Rogers and Walls, 
1980; Lerner et al., 1980; Seif et al., 1979). Such 
potential event has been reported by Woychik et al. 
(1982) for bovine GH gene at exon 3. Another event has 
been reported by Hampson and Rottman (1987) in which 
the inclusion of exon 4 sequence has been reported in 
mRNA for GH. Researchers are in constant search of the 
identification of different motifs in GH involved in different 
functions. GH has its role in a number of anabolic 
functions like protein synthesis, bone elongation and 
growth promoting activity. Availability of naturally 
occurring GH variants has provided some clues 
identifying the functions of different motifs of GH. 
Detection of 20k hGH could be considered as an impor-
tant land mark in this connection. 
Revealing of the fact that GH could be used as a tool 
for increasing farm animals productivity (increase in milk 
and meat production by the exogenous supply of GH) 
has made biotechnologist to pay great attention to this 
molecule (Jones et al., 1994; Mikel, 1993; Seve et al., 
1993; Sillence, 2004; Thatcher, 2002). GH has now been 
successfully produced as a recombinant protein with 
proper folding and is being heavily used in the dairy 
industry. Recombinant GH has been produced as a major 
protein which is a recombinant DNA-derived GH 
molecule in the form of insoluble granules. Bioactivity of 
the recombinant molecule is dependent  on  the  solubility  
 





28 29  30     31      32     33      34      35     36     37      38     39       40 
ACC   TTC   AAA  GAG  TTT  GAG  CGC  ACC  TAC  ATC  CCG  GAG  GGA  
Thr Phe Lys Glu Phe Glu Arg Thr Tyr Ile Pro Glu Gly 
  41 42 43      44      45      46      47     48      49     50      51 
CAG  AGA  TAC   TCC   ATC  CAG  AAC  ACC  CAG  GTT  GCC 




28 29  30     31      32          47     48      49     50      51 
ACC   TTC   AAA   GAG  TTT       AAC  ACC  CAG  GTT  GCC 
Thr Phe Lys Glu Phe   Asn Thr Gln Val Ala  
 
Figure 1(a). Shows the nucleotides and amino acid sequence corresponding to residue 28-51. 
Amino acid residue planned to be deleted are shown in bold. (b). The amino acid sequence and 





and correct folding of the molecule. For this purpose, the 
chemistry of the protein has been extensively studied. 
GH molecule has two disulfide bridges. Correct folding of 
the molecule is linked to the precise formation of these 
two bridges. (Langley et al., 1987(a, b); Storrs et al., 
2001; Baranauskaite, 2005). Tou et al. (2009) has 
reported the generation of two novel bGH species 
generated from a common dehydroalanine intermediate 
under stressed conditions. Borromeo et al. (2008) has 
studied the effects of renaturing and storage conditions of 
mink growth hormone. Introduction of biology compu-
tational tools has helped to uncover chemistry, structure 
and function relationship of GH molecules. De Vos (1992) 
has reported the crystal structure of the molecule. 
Previously, structure function studied with reference to 
molecular modeling has been reported revealing some 
important features of the molecule (Sami, 2007). Earlier a 
ovine growth hormone (oGH) mutant with the deletion of 
32-46 amino acid residues was produced, though 
expressed as a major protein but was unable to refold 
properly and remained insoluble (Sami, 1991) 
The present study was aimed to identify the role of 
domain comprising of 32-46 in bGH/oGH. For this 
purpose, computational biology tools were used and the 
molecule was designed  and  visualized.  Such  study  for  





Plasmid oGH1 was provided for the preparation of deletion mutant 
32-46 by site directed mutagenesis. Production of the mutant has 
been described earlier (Sami, 1991), briefly it is given below: 
 
 
Production of deletion mutant 33-46 of ovine growth hormone 
by site directed mutagenesis 
 
An oligonucleotide was designed to enable the production of 
recombinant DNA derived oGH variant equivalent to 20k hGH, 
involving the deletion of part of loop between helix 1 and helix 2 
(Figure 1). The site directed mutagenesis was carried out according 
to the method as described in Amersham kit for site-directed 
mutagenesis using DNA sequence coding for OGH1 (Wallis and 
Wallis, 1988). The resultant mutant DNA was sequenced by di-
deoxy sequencing method and was transferred to a pUC 8 plasmid 
using Eco R1 and Hind III sites. After transformation into JM109 E. 
coli, the expression of the protein was checked on SDS-PAGE. The 
expressed protein was isolated and refolded as described by Wallis 
and Wallis (1990). 
The solubility and refolding of the protein was checked on SDS-
PAGE. This part of research was presented in a published PhD 
thesis of the author submitted to University of Sussex England U K 
entitled Studies on recombinant DNA derived ovine growth 






   1   2   3   4  
 
Figure 2. SDS_PAGE of total cellular proteins on 10% gel of E.coli 
containing plasmid for the expression of oGH with deletion of 33-46 
amino acid residues.1= bGH and prolactin marker; 2 = Supernatant 
of total cellular proteins of E.coli containing plasmid for the 
expression of oGH with deletion 33-46 amino acid residues; 3 = 
Pellet obtained after refolding of total cellular proteins of E.coli 
containing plasmid for the expression of oGH with deletion 33-46 
amino acid residues. The variant protein visible in the pellet 






Amino acid sequence for bGH accession No. NM_18096 was used 
(as bGH has more than 99% homology with oGH) and amino acid 
33-46 were deleted using computational tool, to make a protein 
equivalent to 20k bGH. Similarly, hGH accession No. AAA72260) 
and 20k hGH (after deleting the amino acid residues 32-46) 
molecules were visualized. The amino acid sequence was 
submitted to EXPASY server and CPH for molecular model (Arnold 
et al., 2006; Schwede et al., 2003; Lund et al., 2002). The model for 
20k bGH and wild type bGH were superimposed, to compare the 
two molecules. Visualized bGH molecule appeared in green while 
20k bGH appeared in pink. All the four models were visualized for 
hydro-phobicity by employing computer program. The hydrophobic 
regions appeared in blue while hydrophilic regions appeared in red. 
To analyze the role of hydrogen bonding for wild type and mutant 
bGH, hydrogen bonds were identified using a display style dialog in 
the view menu of program. Deleted amino acids from wild type hGH 
was used to make 20 k hGH, EAYIPQKYSFLQAPQ. Similarly, 






Production of deletion mutant 33-46 by site directed 
mutagenesis 
 
Site directed mutagenesis for 33-46 deletion  mutant  was  






Figure 3. Molecular model of bGH (green, visible 
in ribbon structure) super imposed on mutant 20K 
bGH appeared in pink cylinders using Accelrys 
DS Visualizer. Previously, the model was 
prepared on Expassy Server. Difference in the 
structure of the two proteins is encircled for amino 
acid residues 33-46 of bGH which are absent in 




carried out using Amersham kit and the method was 
followed. The resultant DNA was sequenced and the 
deletion of 42 bases was noticed in the DNA sequence 
(Figure 1). 
Ovine growth hormone variant, oGH1, with deletion of 
33-46 residues was produced by site-directed muta-
genesis. The protein which was produced in the form of 
insoluble granules was solubilized and attempted to 
refold, using the method employed for refolding of other 
ovine GH variants (Wallis and Wallis, 1990; Sami et al., 
2008). The results showed that the mutant remained 
insoluble and did not refold (Lane 2, Figure 2). 
 
 
Computational biology  
 
Molecular model of bGH was visualized as ribbon model 
in green while 20k bGH molecule appeared in pink in 
cylinders for alpha helices. It was clearly noticed that 
there was no difference in the global geometry of the 
molecule. 20 kb GH molecule followed the twisted helical 
bundle form of the GH molecule arranged in left twisted 
fashion. The difference observed was the shortening of 
the first helix and the removal of the coil between helix 1 
and  2. The   difference   is   encircled   in   Figure 3.  The  
 




deletion of amino acid residues 33-46 did not alter the 
three D structure of the molecule. To further investigate 
the problem, the hydrophobicity of the 20k variant and the 
wild type bGH and hGH were studied. It was revealed 
that the change alter the hydrophobicity of the 20k oGH 
to a greater extent as compared to 20k hGH (Figures 4b 
and 4d). The first helix in case of 20k bGH was 
completely turned hydrophilic while in case of 20k hGH, 
the hydrophobicity was reduced as compared to wild type 
hGH but was not completely altered. When the chemistry 
of the deleted amino acid residues was compared, it was 
revealed that for making 20k oGH molecule at three 
places highly charged amino acid residues E were 
removed at positions 33, 39 and 41, thus converting 
hydrophobic core into hydrophilic region. While in case of 
20k hGH only one E was removed, justifying the 
decrease in the hydrophobicity but not introducing the 
hydrophilicity, as in the case of 20k bGH molecule. 
Hydrogen bonds play an important role in the chemistry 
of the molecule. Hydrogen bonds in the region 28-56 of 
bGH before and after deletion were located. As shown in 
Figures 5a and 5b, all bonds involving Glu 33, Gln 46, 
Pro 38, Arg 42, Tyr 43,Ala 51, Thr 48, Asn 47, (bGH 
Figure 5a) were removed and new bonds were formed 
between Thr 33, Tyr 144, Asn 32, Asn 32 and Ser and 
Asp 153 (Figure 5b). These results obtained by using 
bioinformatics tools confirmed previously reported results 
for recombinant DNA derived oGH molecules having 
deletion of 33-46 amino acid residues (Figures 3 and 4). 
The loop was deleted by site-directed mutagenesis 
leading to the decreased solubility of the molecule with 
the protein being produced as insoluble granules. The 
recombinant protein was insoluble, as the hydrophobicity 





The Growth hormone variants were studied to identify the 
structure and function relationship in the molecule. 20k 
hGH variant has been studied in detail as it has been 
reported to have shown normal growth promoting activity 
and little insulin like activity (Lewis et al., 1986). 20k hGH 
is a result of mRNA splicing as it plays an important role 
in the production of GH and GH like proteins. The 
intervening sequences spliced out of the gene are 
transcribed to mRNA. Human GH variants such as 17.5k 
hGH and 20k hGH are the products of such splicing (as 
reviewed by Wallis, 1985). Earlier Woychick et al. (1982) 
has reported that bGH gene also contained a potential 
alternate RNA splice point at about the same position 
within the third exon (42 nucleotides from the second 
intron). The alternate site ends in AG, contains several 
nucleotides that are consistent with the consensus 
sequence of RNA splicing and has a significant homology 
with the U1 RNA (Seif et al., 1979; Moore et al., 1982; 
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                 C    D  
 
Figure 4. Molecular model of wild type bGH (A) and hGH (C), were 
compared with 20K hGH, deleting amino acid residues 32 - 46 (B) 
and 20K bGH, deleting amino acid residues 33 – 46 (D), for their 
mutant structure. Hydrophobicity decreased from blue to red, 
employed by Accelrys DS Visualizer, previously the model was 
prepared on Expassy Server and CPH Model. (blue colour indicates 





to determine the effects of deletion of 33-46 amino acid 
residues in order to relate the structure to the function of 
the molecule. A mutant protein for oGH1 with deletion of 
33-46 amino acid residues was produced by site directed 
mutagenesis. The sequence analysis of mutant DNA 
showed that the mutant DNA had a deletion of 42 bases 
as compared to the original oGH1 DNA. The mutant DNA 
was transferred to a pUC plasmid and the expression of 
the protein was checked, as described previously (Wallis 
and Wallis, 1988; Sami et al., 2008). The mutant protein 
was expressed under the control of lac promoter. The 
mutant expressed as more or  less  with  equal  efficiency  
 





B.   
 
Figure 5. Hydrogen bonds identified in the region 33 - 46 amino acids in the wild type (A) and mutant (B). 




like the original oGH1 protein expressed as major protein 
(Wallis and Wallis, 1989), as shown in Figure 2. The 
protein was solubilised in 8 M guanidine chloride and was 
refolded, as described previously. It was observed that 
the total mutant protein did not solubilised in the buffer at 
pH 9.5 after treatment for refolding. It showed that the 
refolded protein has minimum solubility, as compared to 
the   wild   type  protein.  20k bGH  molecule  was  super- 
 




imposed on wild type bGH and it was observed that the 
deletion did not alter the three dimensional structure of 
the molecule (Figure 4). Both models fit nicely except the 
part which was deleted from the molecule after the 
removal, of which four helices remained the initial coordi-
nate. 20k hGH has been studied by workers (Lewis et al., 
1978, 1981) and reported that 20k hGH and 22k hGH 
were not very different from each other in a number of 
bioassays but may have reduced insulin like activity. 
Nishikawa et al. (1989) produced 20k GH by recombinant 
DNA technology and reported that the mutant protein 
behaved like hGH in weight gain assays, deletion of a 
part of loop may was compensated for by the flexibility of 
the loop (Sami, 2007). It showed that the 20kGH pro-
duced as mutant by recombinant DNA technology meth-
ods did not alter the folding properties of the molecule. 
For further investigations, as solubility of the molecules 
is an important factor, hydrophobicity of the molecule was 
checked by employing computational biology tools. It was 
observed that the removal of three E from the mutant 
altered hydrophobicity of the molecule converted the 
hydrophobic region into hydrophilic region (Figure 5b). 
While in the case of 20 k hGH deletion, the solubility of 
the molecule was reduced.  
It may be noted that the deletion did not alter the bonds 
formed by Cys 53 indicating that the change did not alter 
the chemistry of refolding, as the hydrophobic core in GH 
molecule is not disturbed which provided a driving force 
to the molecule for refolding (Kauzman, 1959; Sami, 
2007; Tsai, 2001). Perhaps 20k bGH molecule was pro-
duced as a result of mRNA alternate splicing but due to 
its insolubility, it may not be present in the circulation. An 
example which could be quoted in this regard is of 17.5k 
hGH, which has been reported to be the result of 
alternate mRNA splicing in which the mutations in the first 
and sixth base pair have resulted in misplacing of mRNA 
and loss of exon 3, so that GH produced from this 
message lacks amino acid residues 32-71, forming entire 
connecting loop (Nishikawa et al., 1989; de Vos, 1992; 
Lecomte et al., 1987; Sami 2007). Lecomte et al. (1987) 
has produced the variant by recombinant DNA 
technology and reported the instability of the molecule. 
Earlier a C-terminal deletion mutant was produced for 
ovine growth hormone oGH. Deleted 133-146 (loop 
between helix 3 and 4) did not alter the biological activity 
and the refolding of the molecule (Sami et al., 1999). 
Conclusively, the domain comprising of amino acid 
residues 33-46 in bovine GH and ovine GH is involved in 
solubilizing the protein molecule. Its removal (as it 
contains highly charged amino acid residues) could 
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